Danske Bank A S lifted its position in Indivior PLC (NASDAQ:INDV – Free Report) by 90.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,101,966 shares of the company’s stock after buying an additional 524,489 shares during the period. Danske Bank A S’s holdings in Indivior were worth $39,505,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in INDV. TD Waterhouse Canada Inc. purchased a new stake in shares of Indivior during the second quarter valued at approximately $63,000. GAMMA Investing LLC bought a new stake in shares of Indivior during the second quarter valued at approximately $66,000. Farther Finance Advisors LLC increased its position in shares of Indivior by 716.2% during the third quarter. Farther Finance Advisors LLC now owns 3,624 shares of the company’s stock valued at $130,000 after acquiring an additional 3,180 shares in the last quarter. Sterling Capital Management LLC raised its holdings in Indivior by 482.1% in the 3rd quarter. Sterling Capital Management LLC now owns 3,772 shares of the company’s stock worth $135,000 after acquiring an additional 3,124 shares during the last quarter. Finally, Baird Financial Group Inc. purchased a new position in Indivior in the 2nd quarter worth approximately $211,000. Institutional investors own 60.33% of the company’s stock.
Indivior Stock Performance
INDV opened at $28.21 on Monday. The stock has a market capitalization of $3.33 billion, a P/E ratio of 7.88 and a beta of 0.84. The company’s 50-day simple moving average is $34.24 and its two-hundred day simple moving average is $35.48. Indivior PLC has a 52-week low of $27.68 and a 52-week high of $42.81.
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.26. The firm had revenue of $356.00 million for the quarter, compared to the consensus estimate of $329.35 million. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. Research analysts forecast that Indivior PLC will post 3.66 EPS for the current fiscal year.
Indivior Dividend Announcement
The business also recently disclosed a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were issued a dividend of $8.13 per share. The ex-dividend date of this dividend was Tuesday, November 3rd.
Insiders Place Their Bets
In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction that occurred on Thursday, August 27th. The shares were bought at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the transaction, the chief accounting officer directly owned 27,638 shares in the company, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.74% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the company. Barclays upped their price objective on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Weiss Ratings downgraded Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, September 24th. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a report on Friday, October 2nd. Craig Hallum restated a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Finally, Wall Street Zen cut Indivior from a “strong-buy” rating to a “buy” rating in a research note on Saturday, October 31st. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $46.40.
Check Out Our Latest Research Report on Indivior
Indivior Company Profile
Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.
Further Reading
- Five stocks we like better than Indivior
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV – Free Report).
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
